首页> 外文期刊>Neuroepidemiology >Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study.
【24h】

Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study.

机译:与基于临床的队列研究中的标准实践相比,在两项基于社区的队列研究中指导阿尔茨海默氏病临床诊断的决策规则。

获取原文
获取原文并翻译 | 示例
       

摘要

We developed prediction rules to guide the clinical diagnosis of Alzheimer's disease (AD) in two community-based cohort studies (the Religious Orders Study and the Rush Memory and Aging Project). The rules were implemented without informant interviews, neuroimaging, blood work or routine case conferencing. Autopsies were performed at death and the pathologic diagnosis of AD made with a modified version of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria. We compared the positive predictive value of the clinical diagnosis in the two community-based studies to the positive predictive value of the clinical diagnosis of AD made by standard clinical practice in a clinic-based cohort study using AD pathology as the gold standard. Of 306 clinic cases with probable AD, 286 (93.5%) met CERAD neuropathologic criteria for AD; the results were comparable for those with possible AD (51 of 54, 94.4%). Of 141 study subjects with probable AD, 130 (92.2%) met CERAD neuropathologic criteria for AD; the results were lower but acceptable for those with possible AD (26 of 37, 70.3%). The results were similar in secondary analyses using alternate neuropathologic criteria for AD. The clinical diagnosis of AD can be made in community-based studies without the use of informant interviews, neuroimaging, blood work or routine case conferencing. This approach holds promise for reducing the operational costs of epidemiologic studies of aging and AD.
机译:我们在两项基于社区的队列研究(宗教秩序研究和仓促记忆与衰老项目)中制定了预测规则,以指导阿尔茨海默氏病(AD)的临床诊断。该规则的实施无需进行知情人采访,神经影像检查,血液检查或例行例会。死亡时进行尸检,并使用改良版的财团对AD进行病理学诊断,以建立阿尔茨海默氏病(CERAD)标准注册中心。我们比较了两项基于社区的研究中临床诊断的阳性预测价值与在以AD病理学为金标准的基于临床的队列研究中通过标准临床实践对AD临床诊断的阳性预测价值。在306例可能患有AD的临床病例中,有286例(93.5%)符合CERAD的AD神经病理学标准;结果与那些可能患有AD的患者相当(54分中的51分,占94.4%)。在141位可能患有AD的研究对象中,有130位(92.2%)符合CERAD针对AD的神经病理学标准。结果较低,但对于那些可能患有AD的患者来说是可以接受的(26 of 37,70.3%)。使用替代性神经病理学标准进行AD的二级分析结果相似。可以在基于社区的研究中进行AD的临床诊断,而无需使用知情者访谈,神经影像学,血液检查或例行会议。这种方法有望降低衰老和AD流行病学研究的运营成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号